Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as sutimlimab (BIVV009), BIVV009
sutimlimab · 3 trials · 2 indications
An Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study intervention and did not necessarily had to have a causal relationship with the treatment. Serious adverse events (SAEs) were defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity, was a congenital anomaly/birth defect, suspected transmission of any infectious agent via an authorized medicinal product, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the treatment-emergent period (from first dose of study intervention up to 9 weeks after the last dose of study intervention in the current study).
An AE was defined as any untoward medical occurrence in a participant who received study intervention and did not necessarily had to have a causal relationship with the treatment. AESIs were AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required.
A participant was considered a responder: if he or she did not receive blood transfusion from Week 5 through Week 26 (end of treatment) and did not receive treatment for CAD beyond what was permitted per protocol. Additionally, participant's hemoglobin (Hgb) level must have increased to \>=1.5 grams per deciliter (g/dL) from baseline (defined as last Hgb value before administration of first dose of study drug) at treatment assessment timepoint (defined as average of values from the Week 23, 25, and 26 visits). Percentage of responders was calculated together with 95% exact Clopper-Pearson confidence interval (CI).
Adverse Event (AE): any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Treatment emergent serious adverse events (TESAEs) was defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect, was medically important event. Treatment emergent adverse events (TEAEs): AEs that developed, worsened or became serious during the treatment-emergent (TE) period (from first investigational medicinal product \[IMP\] administration in Part B to last IMP administration + 9 weeks follow-up period).
An Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TESAEs was defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the treatment-emergent (TE) period (from the first investigational medicinal product \[IMP\] administration in Part B to the last IMP administration + 9 weeks follow up period).
| Arm | Type | Description |
|---|---|---|
| Sutimlimab | EXPERIMENTAL | Participants with body weight greater than or equal to (\>=) 39 kilograms (kg) to less than (\<) 75 kg and who had completed Part B of CARDINAL or CADENZA study were enrolled in the current study and received sutimlimab (BIVV009) 6.5 grams as intravenous (IV) infusion on Day 0, Day 7, Day 21 and thereafter every 2 weeks (maximum duration: 49 weeks) in the current study. |
| BIVV009/BIVV009 | EXPERIMENTAL | Participants with primary CAD and without a recent history of blood transfusion during the last 6 months prior to enrollment in this study, received an intravenous (IV) infusion of BIVV009 6.5 g (for participants less than \[\<\]75 kilograms \[kg\]) or 7.5 g dose (for participants greater than or equal to \[\>=\]75 kg) on Day 0 and Day 7 and every 14 days thereafter in Part A up to Week 25. Participants who completed Part A per protocol through the end of treatment visit (Week 26), received placebo on Week 26 and continued to receive BIVV009 6.5 or 7.5 g in Part B, every 2 weeks starting at Week 27 for up to an additional 149 weeks (for 6.5 g) or 121 weeks (for 7.5 g). All participants who completed Part A elected to continue in Part B. |
| Placebo/BIVV009 | EXPERIMENTAL | Participants with primary CAD and without a recent history of blood transfusion during the last 6 months prior to enrollment in this study, received an IV infusion of placebo matched to BIVV009 on Day 0 and Day 7 and every 14 days thereafter in Part A up to Week 25. Participants who completed Part A per protocol through the end of treatment visit (Week 26) received BIVV009 6.5 (if \<75 kg) or 7.5 g (if \>=75 kg) in Part B, on Week 26 and Week 27 and every 2 weeks thereafter for up to an additional 123 weeks (for 6.5 g) or 137 weeks (for 7.5 g). All participants who completed Part A elected to continue in Part B. |
| BIVV009 | EXPERIMENTAL | Participants with primary CAD who had a recent history of transfusion (defined as at least 1 transfusion during the last 6 months prior to screening) received an intravenous (IV) infusion of BIVV009 6.5 grams (g) (if body weight was less than \[\<\] 75 kilograms \[kg\]) or BIVV009 7.5 g (if body weight was greater than or equal to \[\>=\] 75 kg) on Day 0 and Day 7 and every 14 days thereafter in Part A up to Week 25. Participants who completed Part A per protocol through the end of treatment visit (Week 26) could continue to receive BIVV009 in Part B, every 2 weeks starting at Week 27 for up to an additional 149 weeks. All participants who completed Part A elected to continue in Part B. |
| Name | Type | Description |
|---|---|---|
| sutimlimab | DRUG | Pharmaceutical form: solution for injection Route of administration: intravenous (IV) |
| sutimlimab (BIVV009) | DRUG | Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.) |
| placebo | DRUG | Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.) |
| BIVV009 | DRUG | Sutimlimab was administered as intravenous (IV) infusion. |
Inclusion Criteria: --Participant must be adults. * Participants who had been enrolled in and had completed Part B of CARDINAL or CADENZA study. * Participants who had ongoing diagnosis of CAD. * Participants who continued to require treatment for CAD upon completion of participation in the previo...
Sutimlimab is used for the treatment of cold agglutinin disease, a rare hematologic disorder in which red blood cells are destroyed by the immune system. It is a monoclonal antibody being developed by Sanofi for this indication and has been studied in Phase 3 clinical trials.
Sutimlimab targets C1S, a component of the complement system. By inhibiting C1S, sutimlimab is designed to block complement-mediated destruction of red blood cells, which is the underlying mechanism of cold agglutinin disease.
Sutimlimab is being developed by Sanofi, which trades under the ticker symbol SNY. Sanofi is responsible for the clinical development program of sutimlimab for cold agglutinin disease.
Sutimlimab is in Phase 3 clinical development for cold agglutinin disease. It has completed two Phase 3 trials, and no active trials are currently listed. It is an investigational agent and has not been approved by the FDA.
Sutimlimab has been studied in two completed Phase 3 trials: NCT03347422, which enrolled 42 participants with primary cold agglutinin disease without a recent history of blood transfusion, and NCT05132127, which enrolled 7 adult participants in Japan who had completed the CARDINAL or CADENZA Phase 3 studies.
Yes, sutimlimab is also known as BIVV009. BIVV009 was the earlier designation used in clinical trial titles, such as NCT05132127 and NCT03347422, and both names refer to the same monoclonal antibody developed by Sanofi.